Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART | Zendy

Anne Derache | Zendy; Collins Iwuji | Zendy; Siva Danaviah | Zendy; Jennifer Giandhari | Zendy; AnneGeneviève Marcelin | Zendy; Vincent Cálvez | Zendy; Túlio de Oliveira | Zendy; François Dabis | Zendy; Deenan Pillay | Zendy; Ravindra K. Gupta | Zendy

Open Access

Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART

Author(s) -

Anne Derache,

Collins Iwuji,

Siva Danaviah,

Jennifer Giandhari,

AnneGeneviève Marcelin,

Vincent Cálvez,

Túlio de Oliveira,

François Dabis,

Deenan Pillay,

Ravindra K. Gupta

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky428

Subject(s) - dolutegravir , abacavir , virology , integrase , integrase inhibitor , medicine , drug resistance , tenofovir , reverse transcriptase , human immunodeficiency virus (hiv) , reverse transcriptase inhibitor , biology , viral load , antiretroviral therapy , gene , polymerase chain reaction , genetics

The WHO recently recommended the use of a new first-line ART containing dolutegravir. We investigated the efficacy of NRTI backbones (tenofovir or abacavir with a cytosine analogue) in low- and middle-income countries where there is significant prior exposure to antiretrovirals and drug resistance to NRTIs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research